VR Adviser LLC Buys 200,000 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

VR Adviser LLC increased its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 6.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,285,620 shares of the company's stock after acquiring an additional 200,000 shares during the period. Oruka Therapeutics makes up 4.4% of VR Adviser LLC's investment portfolio, making the stock its 6th largest position. VR Adviser LLC owned about 9.39% of Oruka Therapeutics worth $63,708,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its position in Oruka Therapeutics by 4,161.2% during the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after buying an additional 1,572,853 shares in the last quarter. Geode Capital Management LLC lifted its position in Oruka Therapeutics by 2,348.6% during the fourth quarter. Geode Capital Management LLC now owns 342,418 shares of the company's stock valued at $6,643,000 after buying an additional 328,434 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Oruka Therapeutics during the fourth quarter valued at approximately $54,000. Wellington Management Group LLP lifted its position in Oruka Therapeutics by 15.8% during the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock valued at $1,844,000 after buying an additional 12,952 shares in the last quarter. Finally, Barclays PLC acquired a new position in Oruka Therapeutics during the fourth quarter valued at approximately $1,446,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wedbush restated an "outperform" rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Thursday, May 15th. Finally, Wolfe Research initiated coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Oruka Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $39.86.

Oruka Therapeutics Stock Up 2.5%

ORKA stock opened at $10.31 on Tuesday. The company has a market capitalization of $386.02 million, a P/E ratio of -1.65 and a beta of 0.25. The company has a 50-day simple moving average of $9.84 and a 200 day simple moving average of $14.56. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. Equities analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Want to see what other hedge funds are holding ORKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.